ArticleJournal, genetic engineering & biotechnology2025
Profile of GAS6 gene single nucleotide polymorphisms [GAS6 c.834+7G>A (rs8191974), and GAS6 c.1332C>T (rs1803628)] among a cohort of Egyptian women with preeclampsia: Relation to disease risk and severity.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study represents the investigation of the potential link between single nucleotide polymorphisms (SNPs) in the growth arrest-specific 6 (GAS6) gene and preeclampsia (PE) in Egyptian women. Few existing research have explored this association in other populations, prompting this investigation into the relationship between variants of GAS6 SNPs and both the probability and severity of PE. 200 pregnant Egyptian women participated in the study; 100 were normotensive, 50 had mild PE, and 50 had severe PE. RFLP-PCR was used to genotype GAS6 SNPs [NM_000820.4:c.834+7G>A (rs8191974) and NM_000820.4:c.1332C>T (rs1803628)] in patients and controls (mean ages 30.33 ± 7.17 and 27.43 ± 5.14 years, respectively). Key findings included a significantly higher frequency of AA genotype (29 % vs. 7 %; P < 0.001) and A allele (56 % vs. 30 %; P < 0.001, OR = 0.337, 95 % CI = 0.223-0.508) of NM_000820.4:c.834+7G>A in PE patients compared to controls. In contrast, the CC genotype (27 % vs. 4 %; P < 0.001) and wild C allele (59.5 % vs. 49.5 %; P = 0.045, OR = 1.499, 95 % CI = 1.009-2.226) of NM_000820.4:c.1332C>T were also significantly more frequent in PE patients. Within PE cases, severe cases showed a higher frequency of the CC genotype of NM_000820.3:c.1332C > T (38 % vs. 16 % in mild cases; P = 0.009) and C allele (68 % vs. 51 %; P = 0.014, OR = 2.042, 95 % CI = 1.149-3.627). These results indicate an association between PE risk and the A allele and AA genotype of NM_000820.4:c.834+7G>A variants. Within this cohort of Egyptian women, PE development and severity were significantly linked to the presence of the CC genotype and C allele of the NM_000820.4:c.1332C>T variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.